Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Abler is an active Australian veterinary pharmaceutical company focused on equine health, especially affordable treatments for horse gastric and hindgut ulcer conditions. The company markets direct-to-customer equine medicines and supportive products through its website, with global shipping. Its flagship commercial products include AbPrazole, an omeprazole-based ulcer treatment, and AbPrazole Plus, which combines omeprazole with a probiotic. Abler also sells sucralfate-based products and adjacent horse-health products such as anti-inflammatories, dewormers, and probiotics. The business appears to be a niche commercial animal-health company rather than a human biotech drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Abler.